lithium has been researched along with Neurodegenerative Diseases in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 7 (38.89) | 2.80 |
| Authors | Studies |
|---|---|
| Majidazar, R; Naseri, A; Rezazadeh-Gavgani, E; Sadigh-Eteghad, S | 1 |
| Gogoleva, IV; Grishina, TR; Gromova, OA; Pronin, AV; Torshin, IY | 1 |
| Abdelaty, AO; Abdelrahman, AI; Aboul Ezz, HS; Ahmed, NA; Ebrahim, YM; El-Feky, AS; Elgohary, A; Elsaeed, H; Fahmy, HM; Ismail, HA; Khadrawy, YA; Mohammed, FF; Mohammed, HS; Noor, NA; Radwan, NM; Sakraan, A; Tharwat, EK | 1 |
| Biagioni, F; Busceti, CL; Fornai, F; Giorgi, FS; Lazzeri, G; Puglisi-Allegra, S | 1 |
| Gruber, J; Kaur, P; Kibat, C; Lam, VYM; Lim, CH; Mathuru, AS; Teo, E; Tolwinski, NS; Zhu, F | 1 |
| Agam, G; Damri, O; Shemesh, N | 1 |
| Alda, M; Khayachi, A; Milnerwood, AJ; Rouleau, GA; Schorova, L | 1 |
| Costemale-Lacoste, JF; Hozer, F; Morlet, É | 1 |
| Al-Maghout, T; Bhuyan, AAM; Hauser, S; Hosseinzadeh, Z; Lang, F; Pelzl, L; Sahu, I; Schöls, L; Stournaras, C; Sukkar, B; Zacharopoulou, N | 1 |
| Ceylan, ME; Cömert, G; Evrensel, A; Ünsalver, BÖ | 1 |
| Fuentes, JM; Gómez-Sánchez, R; González-Polo, RA; Pedro, JM; Pizarro-Estrella, E; Rodríguez-Arribas, M; Yakhine-Diop, SM | 1 |
| Chiu, CT; Chuang, DM | 2 |
| Ledoux, JM | 1 |
| Chuang, DM; Rowe, MK | 1 |
| Chuang, DM | 1 |
| Bhat, R; Burns, M; Dickson, D; Duff, K; Feinstein, B; Gaynor, K; Krishnamurthy, P; LaFrancois, J; Lewis, J; Meyerson, J; Noble, W; Olm, V; Planel, E; Suleman, F; Wang, L; Wen, Y; Zehr, C | 1 |
| Kobayashi, H; Wada, A; Yanagita, T; Yokoo, H | 1 |
11 review(s) available for lithium and Neurodegenerative Diseases
| Article | Year |
|---|---|
Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews.
Topics: Alzheimer Disease; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Cholinesterase Inhibitors; Donepezil; Galantamine; Glycogen Synthase Kinase 3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Indans; Lithium; Melatonin; Memantine; Neurodegenerative Diseases; Rivastigmine; Systematic Reviews as Topic | 2022 |
Lithium engages autophagy for neuroprotection and neuroplasticity: Translational evidence for therapy.
Topics: Autophagy; Humans; Lithium; Neurodegenerative Diseases; Neuronal Plasticity; Neuroprotection | 2023 |
Is There Justification to Treat Neurodegenerative Disorders by Repurposing Drugs? The Case of Alzheimer's Disease, Lithium, and Autophagy.
Topics: Alzheimer Disease; Animals; Apoptosis; Autophagy; Bipolar Disorder; Drug Repositioning; Glycogen Synthase Kinase 3; Homeostasis; Humans; Lithium; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Phosphoric Monoester Hydrolases | 2020 |
Posttranslational modifications & lithium's therapeutic effect-Potential biomarkers for clinical responses in psychiatric & neurodegenerative disorders.
Topics: Biomarkers; Bipolar Disorder; Humans; Lithium; Neurodegenerative Diseases; Protein Processing, Post-Translational | 2021 |
Neuroprotective effects of lithium: what are the implications in humans with neurodegenerative disorders?
Topics: Aged; Aged, 80 and over; Aging; Humans; Lithium; Neurodegenerative Diseases; Neuroprotective Agents | 2018 |
Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Topics: Animals; Autophagy; Disease Models, Animal; Food; Humans; Isothiocyanates; Lithium; Neurodegenerative Diseases; Resveratrol; Sirolimus; Spermidine; Stilbenes; Sulfoxides; Trehalose; Valproic Acid | 2015 |
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.
Topics: Animals; Apoptosis; Bipolar Disorder; Central Nervous System Diseases; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Lithium; Neurodegenerative Diseases; Signal Transduction | 2010 |
Neuroprotective action of lithium in disorders of the central nervous system.
Topics: Animals; Central Nervous System Diseases; Humans; Lithium; Neurodegenerative Diseases; Neuroprotective Agents; Nootropic Agents | 2011 |
Lithium neuroprotection: molecular mechanisms and clinical implications.
Topics: Antimanic Agents; Apoptosis; Bipolar Disorder; Brain Damage, Chronic; Brain Injuries; Excitatory Amino Acid Antagonists; Female; Gene Expression Regulation; Humans; Lithium; Male; Nerve Tissue Proteins; Neurodegenerative Diseases; Neuroprotective Agents; Receptors, N-Methyl-D-Aspartate; Signal Transduction; Stroke | 2004 |
Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases?
Topics: Animals; Cells, Cultured; Humans; Huntington Disease; Lithium; Mice; Neurodegenerative Diseases; Neuroprotective Agents; Nootropic Agents; Rats; Stroke | 2004 |
Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases.
Topics: Acute Disease; Animals; Bipolar Disorder; Brain Injuries; Cells, Cultured; Chronic Disease; Endoplasmic Reticulum Chaperone BiP; Humans; Lithium; Neurodegenerative Diseases | 2005 |
7 other study(ies) available for lithium and Neurodegenerative Diseases
| Article | Year |
|---|---|
[A systematic analysis of neurobiological roles of lithium].
Topics: Bipolar Disorder; Humans; Lithium; Lithium Compounds; Neurodegenerative Diseases; Neuroprotection | 2022 |
Evaluation of the therapeutic potential of cerebrolysin and/or lithium in the male Wistar rat model of Parkinson's disease induced by reserpine.
Topics: Acetylcholinesterase; Animals; Disease Models, Animal; Lithium; Male; Neurodegenerative Diseases; Parkinson Disease; Rats; Rats, Wistar; Reserpine | 2023 |
Application of optogenetic Amyloid-β distinguishes between metabolic and physical damages in neurodegeneration.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Caenorhabditis elegans; Disease Progression; Drosophila; Female; HEK293 Cells; Humans; Light; Lithium; Male; Neurodegenerative Diseases; Optogenetics; Plaque, Amyloid; Zebrafish | 2020 |
Inhibition of Lithium Sensitive Orai1/ STIM1 Expression and Store Operated Ca2+ Entry in Chorea-Acanthocytosis Neurons by NF-κB Inhibitor Wogonin.
Topics: Calcium; Calcium-Transporting ATPases; Cell Differentiation; Cells, Cultured; Flavanones; Gene Expression; Humans; Induced Pluripotent Stem Cells; Lithium; Membrane Potentials; Neoplasm Proteins; Neurodegenerative Diseases; Neurons; NF-kappa B; ORAI1 Protein; Patch-Clamp Techniques; Stromal Interaction Molecule 1; Thapsigargin | 2018 |
Lithium-induced cortical atrophy and cognitive dysfunction.
Topics: Atrophy; Bipolar Disorder; Brain; Cognition; Cognition Disorders; Female; Humans; Lithium; Middle Aged; Neurodegenerative Diseases; Organ Size | 2014 |
Features of the comparative pharmacokinetics of lithium; a potential application of its use in livestock farming.
Topics: Animal Husbandry; Animals; Cattle; Cattle Diseases; Humans; Lithium; Mink; Neurodegenerative Diseases; Neuroprotective Agents; Prion Diseases; Species Specificity | 2003 |
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.
Topics: Animals; Disease Progression; Enzyme Inhibitors; Epitopes; Glycogen Synthase Kinase 3; Humans; Image Processing, Computer-Assisted; Immunoblotting; Immunohistochemistry; Immunoprecipitation; Lithium; Lithium Chloride; Mice; Mice, Transgenic; Neurodegenerative Diseases; Neurons; Phosphorylation; tau Proteins; Tauopathies | 2005 |